Hey guys happy new year to all Immutep supporters and shareholders. What do you think: is a partial outlicensing of efti possible and useful e.g. in the combination with paclitaxel in the indication Metastatic Breast Cancer to Pfizer (AIPAC-003) after knowing the optimal dose of efti? Or for the indication head and neck cancer to Merck?
Every shareholder knows otherwise that Immutep needs more cash with further dilution! This Procedere must be turned and broken otherwise a further volatile sideness behaviour of the share price is my guess.
I am interested in your thoughts and opinions!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.010(4.26%) |
Mkt cap ! $359.6M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.8¢ | 23.5¢ | $309.7K | 1.278M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 435058 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 108906 | 5 |
View Market Depth
| Last trade - 16.10pm 08/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |